Small-Cap Momentum Watch: Upcoming Catalysts for October 19–23
10/19/20269 min read
From operational updates to conference participation, we’ve highlighted the small-cap events that could drive attention this week.
--
Companies Participating at the LD Micro 20th Annual Main Event Conference 2026
The LD Micro 20th Annual Main Event Conference will take place from October 19–21, 2026, in Los Angeles, California. The annual event brings together microcap and emerging-growth public companies, institutional investors, executives, and industry professionals for company presentations, investor meetings, panel discussions, and networking opportunities. Participating companies will have the opportunity to highlight their business strategies, financial performance, growth initiatives, and upcoming milestones while engaging with investors and potential strategic partners across multiple industries.
Participating companies: ACCS, XHLD, CERS, AIAI, RVSN, LINK, KBSX, DIBS, KUST, PMEC, GMEX, HUIZ, VTIX, NOMA, UPXI, ODYS, NAGE, CAST, AIB, CITR, FBDT, CIA, CEPL, BFRG, CREX, USIO, PDC, SATL, PHUN, FRSX, CFND, ZDGE
Companies Participating at the Chardan 10th Annual Healthcare Conference 2026
The Chardan 10th Annual Healthcare Conference will take place on October 20, 2026, at The Lotte New York Palace in New York City. Hosted by Chardan Capital Markets, the annual event brings together healthcare and biotechnology companies, institutional investors, industry executives, and healthcare professionals for company presentations, fireside chats, one-on-one investor meetings, and discussions focused on emerging medical technologies and therapeutic innovations. Under the theme “The Next 10 Years of Disruptive Innovation,†the conference will highlight advancements in oncology, genetic medicines, cell therapies, ophthalmology, pulmonary arterial hypertension, central nervous system disorders, and AI-driven drug delivery, providing participating companies opportunities to showcase clinical development programs, upcoming milestones, and growth strategies.
Participating companies: PRLD, SPRO, RCKT, MNKD, SABS, CAMP, RANI, MGX, WVE, COYA, IRD, LXEO
Companies with Material Events This Week:
LRHC - Will change its corporate name to Stratum Holdings Corp., effective October 19, 2026, at 12:01 a.m. ET. The company's common stock is expected to begin trading on the Nasdaq Capital Market under the new ticker symbol SRTM at market open on October 19. The CUSIP number will remain unchanged, and shareholders are not required to take any action.
ATNM - Will present three preclinical studies of ATNM-400 at the 39th Annual Congress of the European Association of Nuclear Medicine (EANM), taking place October 17-21, 2026, in Vienna, Austria. An oral presentation on October 19 will highlight durable antitumor responses in KRAS- and ALK-driven non-small cell lung cancer models, while two additional e-posters will cover ATNM-400's potential in colorectal and ovarian cancer models.
BIVI - Will present Phase 2 clinical trial findings at the American Neurological Association Annual Meeting (ANA2026), October 17-20, 2026, in San Diego. Two posters will highlight results from the ADDRESS-LC trial in Long COVID and the SUNRISE-PD trial evaluating bezisterim (NE3107) in Parkinson's disease. The SUNRISE-PD presentation is scheduled for October 19 from 5:30-7:00 p.m.
AIB - Will host a virtual investor webinar on October 22, 2026, at 4:15 p.m. ET. CEO Jerry Tang and CFO Jolienne Halisky will discuss the company's AI and high-performance computing infrastructure strategy, data center portfolio, customer agreements, financing initiatives, recent corporate milestones, and growth opportunities, followed by a live Q&A session.
LGVN - Will participate in the Longevity Partnering Forum, taking place October 19-20, 2026, in South San Francisco, California. The event brings together biotechnology companies, investors, and industry professionals to discuss advances in longevity-focused therapeutics, research, and potential development partnerships.
PALI - Will present four studies of its lead drug candidate PALI-2108 at United European Gastroenterology Week 2026, October 17-20, in Barcelona, Spain. Presentations include Phase 1b findings in fibrostenotic Crohn's disease, favorable safety and gut-targeted drug exposure, early clinical responses in ulcerative colitis, and development of a transcriptomic biomarker to predict treatment response. Three moderated poster presentations are scheduled for October 19-20.
KOPN - Will host a live YouTube Ask Me Anything event titled "The Trillion Dollar AI Bottleneck" on October 20, 2026, at 11:00 a.m. ET, streamed from Nasdaq MarketSite. The discussion will focus on artificial intelligence and related technology challenges and opportunities.
APRE - Will host a virtual panel discussion titled "The State of WEE1 Inhibition in Precision Oncology" on October 20, 2026, at 11:00 a.m. ET. The event will feature oncology and financial-market experts discussing WEE1 inhibition, DNA damage response therapies, drug selectivity challenges, and upcoming scientific and clinical developments ahead of ESMO Congress 2026.
NTHI - Executive Chairman and CEO Amir Heshmatpour will participate in the Abu Dhabi Future Health Summit, October 20-22, 2026, in Abu Dhabi, UAE. On October 22, he will join the "Investment Lens: Banking on Prediction" panel focused on life sciences investment and international partnerships, following the company's recent UAE clinical development authorizations for NEO100 and NEO212.
OBAI - Founder and CEO Doron Kempel will host a live investor webinar on October 20, 2026, at 11:00 a.m. ET. Management will highlight recent business momentum, key corporate developments, ongoing growth initiatives, and the outlook for the company's AI-powered preventative personal security platform.
BIAF - Will sponsor a Learning Theater presentation at CHEST 2026 on October 21, 2026, from 12:30-1:15 p.m. MST in Phoenix, Arizona. Chief Medical Officer Dr. Gordon Downie will discuss CyPath Lung's role in lung cancer risk stratification and pulmonary nodule management, along with positive research data supporting the development of an investigational test for asthma- and COPD-related lung inflammation.
HOVR - Management will participate in the Best Defence Conference, October 20-21, 2026, in London, Ontario. The company will deliver a presentation during the event's Technology Showcase and meet with industry participants to discuss its aerospace and defense technologies and potential business opportunities.
ANIX - Will participate in a RedChip investor webinar on October 20, 2026, at 4:15 p.m. ET. CEO Dr. Amit Kumar will provide updates on the company's two clinical-stage oncology programs, including its lira-cel CAR-T therapy for ovarian cancer and breast cancer vaccine program. The presentation will review Phase 1 lira-cel clinical progress, early patient observations, dose escalation, and additional patient-level data expected over the coming months.
SUNE - Founder and CEO Scott Maskin will speak at the HIA-LI Energy Conference on October 23, 2026. The discussion will focus on rising electricity demand from AI, data centers, and electrification, evolving New York energy policies, grid reliability, and opportunities for distributed solar and backup power solutions.
SVRA - Will present Phase 3 IMPALA-2 and Phase 2/3 IMPALA clinical trial data for molgramostim at CHEST 2026, October 18-21, in Phoenix, Arizona. An encore oral presentation on October 20 will highlight long-term efficacy and safety in autoimmune pulmonary alveolar proteinosis, while an October 21 poster will examine treatment effects in patients with mild diffusion impairment.
VUZI - Will participate in the PECC Summit, October 20-21, 2026, in Sunnyvale, California. Management will host meetings with AI data center, semiconductor, photonics, and advanced packaging companies to review its Vuzix Causeway waveguide optical interconnect evaluation platform and discuss potential evaluation and collaboration opportunities.
MAMO - Will publicly showcase its new Warrior 1500 UTV at Equip Exposition 2026, taking place October 20-23 in Louisville, Kentucky. The event will provide an opportunity to introduce the new vehicle to industry professionals, dealers, and prospective customers.
MCRB - Will present preclinical data supporting SER-428, its investigational oral liquid live biotherapeutic product designed to reduce bloodstream infections in high-risk patients following sepsis and antibiotic exposure, at IDWeek 2026 in Washington, D.C. The poster presentation is scheduled for October 22 from 12:15-1:30 p.m. EDT.
CNTN - Will host a live investor webinar on October 21, 2026, at 11:00 a.m. ET to discuss its newly released Q3 2026 Canton Network ecosystem report. The discussion will highlight institutional adoption, six new Super Validators, completion of DTCC's pilot involving more than 30 financial firms, Broadridge's DLX tokenization platform, and preparations for DTCC Tokenization Services expected to launch in late October.
ELTX - Will present new prespecified analyses and complete results from its randomized Phase 2 AMPLIFY-7P study of ELI-002 7P in resected pancreatic cancer at ESMO Congress 2026 in Madrid, Spain. The late-breaking oral presentation is scheduled for October 23, 2026, during the 1:30-3:00 p.m. CEST session. The findings will provide additional clinical and biological data to inform the company's potential Phase 3 development strategy.
HUMA - Will present interim results from its V012 Phase 3 clinical trial in a late-breaking oral presentation at the American Society of Nephrology Kidney Week 2026, October 21-25, in Denver, Colorado (Thursday, October 22, at 4:40-4:50 p.m. MT). The randomized study compares the company's acellular tissue engineered vessel (ATEV) with autogenous arteriovenous fistula for hemodialysis access in female patients with end-stage kidney disease.
ELDN - Will present patient-reported outcomes from its Phase 2 BESTOW clinical trial evaluating tegoprubart versus tacrolimus for the prevention of kidney transplant rejection at ASN Kidney Week 2026. The oral presentation is scheduled for October 23, 2026, from 4:40-4:50 p.m. MDT, highlighting patient-reported outcomes in kidney transplant recipients.
ARDX - Will present three research abstracts at ASN Kidney Week 2026, October 21-25, in Denver, Colorado. All three posters are scheduled for October 23 and will cover real-world effectiveness of tenapanor with phosphate binders, patient experiences managing hyperphosphatemia, and the relationship between long-term elevated phosphate levels and morbidity and mortality in dialysis patients.
IFRX - Will present a late-breaking preclinical poster at ASN Kidney Week 2026 on October 22, from 10:00 a.m.-12:00 p.m. The presentation will highlight izicopan, its second-generation oral C5a receptor 1 antagonist, and preclinical findings supporting its therapeutic potential in kidney disease models.
PROK - Will present eight abstracts, including one oral presentation, at ASN Kidney Week 2026, October 21-25, in Denver, Colorado. The presentations will highlight rilparencel's mechanism of action, kidney tissue repair, manufacturing characteristics, and clinical findings from its Phase 2 chronic kidney disease program. The October 23 oral presentation at 5:40 p.m. MDT will examine graft-adjacent remodeling and vascular integrity, while posters from October 22-24 will include pooled Phase 2 safety and efficacy data relevant to the ongoing Phase 3 PROACT 1 study.
ICU - Will present late-breaking post-approval SAVE Registry data evaluating its Selective Cytopheretic Device for pediatric patients with sepsis-associated acute kidney injury at ASN Kidney Week 2026. The poster, scheduled for October 22 from 10:00 a.m.-12:00 p.m. MT, will compare outcomes from the SCD-PED surveillance registry with a historical patient cohort.
NUWE - Will participate in the American Society of Nephrology Kidney Week 2026, October 21-25, at the Colorado Convention Center in Denver. The company will exhibit at Booth 391, engaging kidney-care professionals and industry participants regarding advances in critical care nephrology, pediatric care, heart failure, and related treatment technologies.
LABT - Will present preclinical data from its Nu-3 program in a scientific poster at IDWeek 2026 on October 22 in Washington, D.C. Dr. Cooper will deliver the presentation following the company's participation in the Maxim Growth Summit and ThinkEquity Conference earlier in October.
AKBA - Will have multiple clinical and research presentations at ASN Kidney Week 2026, October 21-25, in Denver, Colorado. A late-breaking October 23 presentation at 12:00 p.m. MT will feature results from the VOICE trial evaluating three-times-weekly vadadustat versus an erythropoiesis-stimulating agent in hemodialysis patients. Additional presentations October 22-24 will cover praliciguat in focal segmental glomerulosclerosis, ebribafusp alfa in complement-mediated kidney diseases, and clinical and economic outcomes associated with Vafseo.
MDAI - Will participate in the Midwest Region Burn Conference, October 22-23, 2026, in Columbus, Ohio. The conference brings together burn-care specialists, clinicians, and medical technology professionals to discuss advances in burn treatment, clinical practices, patient care, and emerging technologies.
WPRT - Will transition to its new corporate name, Aetherion Technologies Inc., with shares expected to begin trading under the new ticker symbol AETR on Nasdaq and the Toronto Stock Exchange on or about October 23, 2026, subject to final exchange approvals. The rebranding reflects the company's focus on commercially ready technologies for lower-emission heavy-duty transportation. The company's CUSIP and ISIN numbers will also change.
SOAR - Will complete its planned corporate rebranding to SOAR AI, Inc., with the name change expected to become effective October 19, 2026, and trading under the new corporate name expected to begin on the NYSE American on October 20, 2026, subject to applicable approvals. The company will retain its existing ticker symbol SOAR. The rebranding follows its merger with Alignment Engine and reflects its transition toward AI infrastructure and AI-powered software platforms.
--
Disclaimer: All content provided by BigTimePennys Report is for informational purposes only. The information provided should not be considered as a substitute for professional advice, analysis, or guidance. Any investment decisions made based on the information provided are solely at the user's own risk. BigTimePennys Report are not liable for any losses or damages incurred as a result of using this information. BigTimePenny is not operated by a licensed broker, a dealer, or a registered investment adviser. The Securities Litigation Reform Act of 1995 provides safe harbor protection for forward-looking statements made by companies or individuals. It should be noted that any forward-looking statements made by BigTimePennys Report, its authors, are not guarantees of future performance or results. These statements are subject to risks, uncertainties, and assumptions that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. The content provided by BigTimePennys Report does not constitute an endorsement, recommendation, or solicitation to buy, sell, or hold any securities or investment products. BigTimePennys Report, its authors, do not endorse or recommend any specific investment strategies, securities, or companies. It is crucial to conduct thorough research and seek advice from a qualified professional before making any investment decisions. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. The user assumes full responsibility for the use of the information provided by BigTimePennys Report. BigTimePennys Report, its authors, disclaim any liability for any direct, indirect, or consequential damages arising from the use or reliance on the information provided. Users should exercise their own judgment and discretion when interpreting and utilizing the information provided. Please note that the content provided by BigTimePennys Report is based on available information and sources believed to be reliable. However, market conditions and regulations may change over time, and there may be inaccuracies or errors in the information provided. It is recommended to verify the information with current and reliable sources before making any investment decisions. Investing in micro-cap companies is highly speculative and carries an extremely high degree of risk. BigTimePenny is not a fiduciary by virtue of any person's use of or access to this content. We were NOT compensated for this article.
Disclaimer: Penny stock trading involves substantial risk, so always research every alert before trading, consult with a licensed professional before trading, only invest what you can afford to lose, and always trade with caution. Readers should independently investigate and fully understand all risks before investing. Results listed are NOT typical and individual results may and most likely will vary. Bigtimepennystocks.com and its staff are NOT licensed investment advisors or broker/dealers of any kind.Alerts are not a solicitation or recommendation to buy/sell/hold securities but merely investment ideas that should NEVER serve as the basis of your trading decisions. Bigtimepennystocks.com and its newsletter are for entertainment purposes only. This website and its reports are for general information purposes as we are engaged in the business of marketing and advertising companies for monetary compensation. Any investment decision should be discussed with a financial adviser before taking place. Please invest carefully and read investment information available at the website of the SEC at http://www.sec.gov.
Subscribe to our Free Newsletter
Copyright © 2023 BigTimePennyStocks.com - All Rights Reserved.